Immuron CEO Steven Lydeamore to Speak at Emerging Growth Conference

Immuron Limited, an Australian biopharmaceutical company listed on both the Australian Securities Exchange (ASX: IMC) and the NASDAQ (NASDAQ: IMRN), has announced that its CEO, Steven Lydeamore, will be presenting at the Emerging Growth Conference on June 13th, 2024. The event will provide an opportunity for individual and institutional investors, as well as advisors and analysts, to attend Immuron's interactive presentation. The presentation will be held at 2:00 PM US Eastern Standard Time and will last for 12 minutes. Attendees are encouraged to register in advance to ensure participation and receive updates.

Steven Lydeamore's presentation will be followed by a Q&A session, where participants can ask questions either in advance or during the event. Questions can be submitted beforehand to Questions@EmergingGrowth.com. For those unable to attend the live event, an archived webcast will be accessible on EmergingGrowth.com and the Emerging Growth YouTube Channel.

The Emerging Growth Conference is designed to allow public companies to efficiently present new products, services, and major announcements to the investment community. The conference targets companies with strong management teams, innovative products and services, and significant long-term growth potential. The audience for the conference includes individual investors, institutional investors, investment advisors, and analysts. All sessions are conducted through video webcasts in the Eastern time zone.

Immuron Limited specializes in developing and commercializing orally administered polyclonal antibodies for the treatment of infectious diseases. One of its key products, Travelan®, is a passive immunotherapy designed to reduce the risk of travelers' diarrhea. Travelan® is composed of hyper-immune bovine antibodies that, when taken with meals, bind to diarrhea-causing bacteria to prevent colonization and associated symptoms. In Australia, Travelan® is listed on the Australian Register for Therapeutic Goods and is marketed to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders. In Canada, it is recognized as a licensed natural health product, while in the United States, it is available as a dietary supplement for digestive tract protection.

Travelers' diarrhea (TD) is defined by the passage of three or more unformed stools within 24 hours, accompanied by symptoms such as nausea, vomiting, abdominal cramps, or fever. It is a common health issue for travelers visiting lower- and middle-income regions. TD poses a significant health risk for deployed U.S. military personnel, who are particularly susceptible due to their environments. The leading causes of TD among deployed forces include diarrheagenic E. coli, Campylobacter spp., and Shigella spp.

Immuron's platform technology utilizes engineered hyper-immune bovine colostrum to produce polyclonal immunoglobulins (IgG) targeted at enteric pathogens. These immunoglobulins are orally active and resistant to digestion, maintaining their activity within the gastrointestinal tract. This technology enables the development of treatments for a wide range of infectious diseases by blocking pathogens and neutralizing their toxins at mucosal surfaces.

One such product developed using Immuron's platform technology is IMM-124E. This product is derived from the colostrum of cattle immunized with a vaccine containing antigens from human-derived enterotoxigenic E. coli (ETEC). The resulting hyperimmune colostrum contains high levels of antibodies specific to ETEC antigens. These antibodies demonstrate strong binding and neutralizing activity against a variety of ETEC strains and their associated toxins. IMM-124E is manufactured into tablet form and marketed as Travelan®.

In summary, Immuron Limited continues to advance its biopharmaceutical developments and will share its progress at the upcoming Emerging Growth Conference. Through its innovative products like Travelan®, the company aims to address significant infectious disease challenges, particularly for travelers and deployed military personnel.